SAR408701 in Patients With CEACAM5-positive Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
-To assess the antitumor activity of SAR408701 in metastatic breast cancer (mBC) and
metastatic pancreatic adenocarcinoma (mPAC)
Secondary Objective:
- To assess the safety and tolerability of SAR408701
- To assess other efficacy parameters of SAR408701
- To assess the immunogenicity of SAR408701